化疗联合抗pd -1/PD-L1新辅助治疗可操作性参数变化分析

Q3 Medicine

Cancer treatment and research communications Pub Date : 2025-01-01 DOI:10.1016/j.ctarc.2025.100910

M Sereno , A Collazo-Lorduy , Y Garitaonaindia , D Gómez de Antonio , J Baena Espinar , C Aguado de la Rosa , P Cruz Castellanos , S Falagán Martínez , LE Chara Valverde , R López-Castro , A López-Martin , J Rubio-Pérez , A Gómez Rueda , C Traseira Puchol , X Mielgo Rubio , B Losada Vila , J Rogado , E Bernal Hertfelder , L Gutiérrez Sainz , JL Campo-Cañaveral , E Casado Sáenz

{"title":"化疗联合抗pd -1/PD-L1新辅助治疗可操作性参数变化分析","authors":"M Sereno , A Collazo-Lorduy , Y Garitaonaindia , D Gómez de Antonio , J Baena Espinar , C Aguado de la Rosa , P Cruz Castellanos , S Falagán Martínez , LE Chara Valverde , R López-Castro , A López-Martin , J Rubio-Pérez , A Gómez Rueda , C Traseira Puchol , X Mielgo Rubio , B Losada Vila , J Rogado , E Bernal Hertfelder , L Gutiérrez Sainz , JL Campo-Cañaveral , E Casado Sáenz","doi":"10.1016/j.ctarc.2025.100910","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The adoption of combined chemotherapy (CT) and immunotherapy (IO) has advanced neoadjuvant therapy (NA) for non-small cell lung cancer (NSCLC), but data on functional impacts are limited. This multicenter retrospective study evaluates respiratory function in NSCLC patients undergoing NA.</div></div><div><h3>Methods</h3><div>From 2020 to 2024, 186 patients treated with CT or CT-IO (anti-PD-1/PD-L1) were analyzed. Respiratory tests (DLCO, FEV1, FVC) pre- and post-NA were compared, alongside clinical, pathological, and surgical variables.</div></div><div><h3>Results</h3><div>Median age: 68; 66.6 % male; 93 % smokers/ex-smokers, histologies: Squamous and adenocarcinoma (46 % each), DLCO decline was greater in CT-IO vs. CT (-12.6 % vs. -7.8 %, <em>p</em> = 0.007) and CT-IO showed increased FEV1 (+3.8 % vs. -2.5 %, <em>p</em> = 0.001) and FVC (+3.7 % vs. -0.7 %, <em>p</em> = 0.003), surgery rate: 85.7 % (lobectomy most common at 83.3 %) and no differences in complications were found except for 9 immune-mediated events in CT-IO.</div></div><div><h3>Conclusions</h3><div>CT-IO impacts DLCO more but improves FEV1 and FVC compared to CT. These findings warrant further validation in prospective studies.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100910"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1\",\"authors\":\"M Sereno , A Collazo-Lorduy , Y Garitaonaindia , D Gómez de Antonio , J Baena Espinar , C Aguado de la Rosa , P Cruz Castellanos , S Falagán Martínez , LE Chara Valverde , R López-Castro , A López-Martin , J Rubio-Pérez , A Gómez Rueda , C Traseira Puchol , X Mielgo Rubio , B Losada Vila , J Rogado , E Bernal Hertfelder , L Gutiérrez Sainz , JL Campo-Cañaveral , E Casado Sáenz\",\"doi\":\"10.1016/j.ctarc.2025.100910\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The adoption of combined chemotherapy (CT) and immunotherapy (IO) has advanced neoadjuvant therapy (NA) for non-small cell lung cancer (NSCLC), but data on functional impacts are limited. This multicenter retrospective study evaluates respiratory function in NSCLC patients undergoing NA.</div></div><div><h3>Methods</h3><div>From 2020 to 2024, 186 patients treated with CT or CT-IO (anti-PD-1/PD-L1) were analyzed. Respiratory tests (DLCO, FEV1, FVC) pre- and post-NA were compared, alongside clinical, pathological, and surgical variables.</div></div><div><h3>Results</h3><div>Median age: 68; 66.6 % male; 93 % smokers/ex-smokers, histologies: Squamous and adenocarcinoma (46 % each), DLCO decline was greater in CT-IO vs. CT (-12.6 % vs. -7.8 %, <em>p</em> = 0.007) and CT-IO showed increased FEV1 (+3.8 % vs. -2.5 %, <em>p</em> = 0.001) and FVC (+3.7 % vs. -0.7 %, <em>p</em> = 0.003), surgery rate: 85.7 % (lobectomy most common at 83.3 %) and no differences in complications were found except for 9 immune-mediated events in CT-IO.</div></div><div><h3>Conclusions</h3><div>CT-IO impacts DLCO more but improves FEV1 and FVC compared to CT. These findings warrant further validation in prospective studies.</div></div>\",\"PeriodicalId\":9507,\"journal\":{\"name\":\"Cancer treatment and research communications\",\"volume\":\"43 \",\"pages\":\"Article 100910\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment and research communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468294225000474\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294225000474","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

采用联合化疗（CT）和免疫治疗（IO）是治疗非小细胞肺癌（NSCLC）的先进新辅助治疗（NA），但对功能影响的数据有限。这项多中心回顾性研究评估了接受NA治疗的非小细胞肺癌患者的呼吸功能。方法对2020 - 2024年186例接受CT或CT- io （anti-PD-1/PD-L1）治疗的患者进行分析。比较na前后的呼吸测试（DLCO、FEV1、FVC），以及临床、病理和手术变量。中位年龄：68岁；66.6%为男性；93%吸烟者/戒烟者，组织学：鳞状癌和腺癌（各占46%），CT- io的DLCO下降比CT更大（- 12.6%比- 7.8%,p = 0.007）， CT- io显示FEV1（+ 3.8%比- 2.5%,p = 0.001）和FVC（+ 3.7%比- 0.7%,p = 0.003）增加，手术率：85.7%（肺叶切除术最常见，为83.3%），除CT- io中9例免疫介导事件外，并发症无差异。结论与CT相比，sct - io对DLCO的影响更大，但能改善FEV1和FVC。这些发现值得在前瞻性研究中进一步验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1

Background

The adoption of combined chemotherapy (CT) and immunotherapy (IO) has advanced neoadjuvant therapy (NA) for non-small cell lung cancer (NSCLC), but data on functional impacts are limited. This multicenter retrospective study evaluates respiratory function in NSCLC patients undergoing NA.

Methods

From 2020 to 2024, 186 patients treated with CT or CT-IO (anti-PD-1/PD-L1) were analyzed. Respiratory tests (DLCO, FEV1, FVC) pre- and post-NA were compared, alongside clinical, pathological, and surgical variables.

Results

Median age: 68; 66.6 % male; 93 % smokers/ex-smokers, histologies: Squamous and adenocarcinoma (46 % each), DLCO decline was greater in CT-IO vs. CT (-12.6 % vs. -7.8 %, p = 0.007) and CT-IO showed increased FEV1 (+3.8 % vs. -2.5 %, p = 0.001) and FVC (+3.7 % vs. -0.7 %, p = 0.003), surgery rate: 85.7 % (lobectomy most common at 83.3 %) and no differences in complications were found except for 9 immune-mediated events in CT-IO.

Conclusions

CT-IO impacts DLCO more but improves FEV1 and FVC compared to CT. These findings warrant further validation in prospective studies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.